A case of myasthenia gravis and myositis induced by nivolumab

Clinical Neurology

Volumn 57, Issue 7, 2017, Pages 373-377

  Konoeda, Fumie ^a   Suzuki, Shigeaki ^b   Nishimoto, Yoshinori ^a   Hoshino, Haruhiko ^a   Takagi, Makoto ^a  

^a SAISEIKAI CENTRAL HOSPITAL   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Immune checkpoint inhibitors; Myasthenia gravis; Myositis; Nivolumab

Indexed keywords

IMMUNOGLOBULIN; NIVOLUMAB; PREDNISOLONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CASE REPORT; COLON CANCER; DYSPNEA; ENDOTRACHEAL INTUBATION; FEMALE; HEAD AND NECK DISEASE; HUMAN; IMMUNOTHERAPY; LABORATORY TEST; LIMB WEAKNESS; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; MYASTHENIA GRAVIS; MYOSITIS; NECK WEAKNESS; NEUROLOGIC EXAMINATION; PLASMA EXCHANGE; POSITIVE END EXPIRATORY PRESSURE; PTOSIS; CHEMICALLY INDUCED; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MYASTHENIA GRAVIS; PLASMA EXCHANGE; POSITIVE-PRESSURE RESPIRATION; PREDNISOLONE; PROGRAMMED CELL DEATH 1 RECEPTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 85026526029     PISSN: 0009918X     EISSN: None     Source Type: Journal    
DOI: 10.5692/clinicalneurol.cn-000991     Document Type: Article

References (17)

1. Robert C, Long GV Brady B, et al. Nivolmab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-330.
2. Weber JS, D'Angel SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-384.
3. Wang C, Thudium KB, Han M, et al. In vitro characterization of the ant-PD-1 antibody nivolmab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2014;2:846-856.
4. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
5. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolmab. J Clin Oncol 2014;32:1020-1030.
6. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-1833.
7. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
8. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial. Lancet Oncol 2015;16:908-918.
9. Jan 21. [cited 2016 Sep. 3]. Available from: http://www.jsmo.or.jp/. Japanese.
10. Dec. 11. [cited 2016 Sep. 3]. Available from: http://www.haigan. gr.jp/uploads/photos/1078.pdf.
11. Kimura T, Fukusima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolmab. Cancer Sci 2016;107:1055-1058.
12. Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolmab in a patient with melanoma. Jpn J Clin Oncol 2016;46:86-88.
13. May. [cited 2016 Sep. 3]. Available from: https://www.opdivo.jp/contents/pdf/open/guide.pdf.
14. Loochtan A, Nickolich M, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 2015;52:307-308.
15. Polat P, Donofrio PD. Myasthenia gravis induced by nivolmab therapy in a patient with non-small-cell lung cancer. Muscle Nerve 2016;54:507.
16. Sciacca G, Nicoletti A, Rampello L, et al. Benign form of myasthenia gravis after nivolmab treatment. Muscle Nerve 2016;54:507-509.
17. Suzuki S, Utsugisawa K, Yoshikawa H, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 2009;66:1334-1338.